ProMIS Neurosciences, Inc. Quarterly report [Sections 13 or 15(d)]

NET INCOME (LOSS) PER SHARE- Outstanding potentially dilutive common shares (Details) - shares	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	68,924,354	57,835,201
Options issued and outstanding under stock option plan
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	4,532,860	1,087,493
Warrants
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	64,390,433	56,746,647
Deferred Share Units
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	1,061	1,061